Pharmacyte Biotech Inc. (PMCB) 0.1044 $PMCB
Cannabis-Infused Consumer Products Fuel a Series of New Launches, Spin-Offs, Acquisitions & Growth Opportunities As Legalized Operations Continue to Expand Nationally
PR Newswire - Tue Jul 14, 7:45AM CDT
As more and more states move to legalizing cannabis & marijuana and while other states are now allowing medicinal use of the drug, venture capital & money has poured into companies that seem poised to profit from cannabis-based products, drugs & applications used for treating various illnesses and diseases. Cannabis Operations Companies worth noting are North American Cannabis Holdings, Inc. (OTC: USMJ), Totally Hemp Crazy, Inc. (OTC: THCZ), Hemp, Inc. (OTC: HEMP), Medbox, Inc. (OTC: MDBX) and PharmaCyte Biotech (OTC: PMCB).
INSY: 39.89 (+0.70)
PharmaCyte Biotech's Cell-in-a-Box Technology Makes Good Cancer Drugs Better
Marketwired - Mon Jul 13, 8:02AM CDT
While many biotech companies are working on new oncology drugs, what's often unappreciated about cancer treatments is how a key improvement in the way drugs are delivered can make a world of difference in their effectiveness. A young and enterprising biotechnology R&D firm called PharmaCyte Biotech (OTCQB: PMCB) understands this, and has not only embraced the benefit of improved dosing methods, but has developed a breakthrough that could change the way we altogether think about pharmaceuticals.
Penny Stocks Research for Thinspace, Pharmacyte Biotech, MaryJane, TOTALLY HEMP CRAZY, EKSO BIONICS, and Anavex Life Sciences
PR Newswire - Fri Jul 10, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Thinspace (OTCMKTS:THNS), Pharmacyte Biotech (OTCMKTS
MCB), MaryJane (OTCMKTS:MJMJ), TOTALLY HEMP CRAZY (OTCMKTS:THCZ), EKSO BIONICS (OTCBB:EKSO), and Anavex Life Sciences (OTCMKTS:AVXL).
PharmaCyte Biotech Appoints American Stock Transfer as New Stock Transfer Agent
GlobeNewswire - Thu Jul 09, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that, effective July 10, 2015, American Stock Transfer & Trust Company ("AST"
will replace Signature Stock Transfer as its stock transfer and dividend disbursing agent.
Small Cap IR Initiates Analyst Coverage - PharmaCyte Biotech Drug Delivery Platform Limited only by Imagination
PR Newswire - Thu Jul 09, 8:15AM CDT
Small Cap IR issues report: PharmaCyte Biotech, Inc. (OTCQB: PMCB) "Cell-in-a-Box" platform exhibits significant potential. Any cell type could potentially be implanted in the body without need for administration of any drugs that decrease the body's immune response. This is important for potential therapies and will dramatically increase versatility and value of this technology into the future. The PMCB platform is a cellulose based "bead" containing live cells. The porous nature of the beads allowed nutrients to enter and support the health of the encapsulated cells. In addition, beads are porous enough to permit activated drugs or other biological substances to leave and provide benefit to their surrounding environment.
Penny Stocks Alerts for Liquidmetal Technologies, MaryJane Group, Thinspace Technology, Pharmacyte Biotech, COIN CITADEL, and Local Corporation
PR Newswire - Tue Jun 30, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Liquidmetal Technologies (OTCMKTS:LQMT), MaryJane Group (OTCMKTS:MJMJ), Thinspace Technology (OTCMKTS:THNS), Pharmacyte Biotech (OTCMKTSMCB), COIN CITADEL (OTCMKTS:CCTL), and Local Corporation (NASDAQ:LOCM).
LOCM: 0.09 (+0.03)
PharmaCyte Biotech Releases HealthWatch Segment Featured on Discovery Channel
GlobeNewswire - Tue Jun 30, 7:30AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its technology and treatments were featured on the Discovery Channel and ION Network this morning. Discovery Channel and ION Network's news magazine series, "NewsWatch," aired the company's story in a 3:42 "HealthWatch" segment that highlighted the companies efforts to bring both cancer and diabetes treatments to market.
With the Mainstream Accepting The Use of Cannabis-Infused Products, Treats & Beverages, New & Innovative Operations Continue to Lead to Growth in the Cannabis Industry
PR Newswire - Tue Jun 30, 7:30AM CDT
As additional states nationwide ease restrictions and prepare for legalized marijuana & hemp availability and new cannabis-infused products and services are introduced to consumers, it's high time that the U.S. mainstream were able to consume cannabis legally at cafes, bistros, bars and restaurants. Cannabis Companies in focus are: North American Cannabis Holdings, Inc. (OTC: USMJ), Totally Hemp Crazy Inc. (OTC: THCZ), PharmaCyte Biotech (OTC: PMCB), Easton Pharmaceuticals Inc. (OTC: EAPH), Hemp, Inc. (OTC: HEMP) and The MaryJane Group, Inc. (OTC:MJMJ)
3 Small-Cap Biotech Stocks That Are Challenging the Status Quo
ACCESSWIRE - Mon Jun 29, 8:01AM CDT
WHITEFISH, MT / ACCESSWIRE / June 29, 2015 / Small-cap biotech stocks have been top performers so far this year, with the PowerShares S&P SmallCap Healthcare ETF (NASDAQ: PSCH) returning 25%, which is 5x better than the SPDR S&P 500 ETF's (NYSE: SPY) 5% return. Investors may want to consider adding exposure to this asset class given its outperformance and lower correlation with the overall U.S. equity market.
SPY: 210.61 (-0.07), PSCH: 73.60 (-0.49), AXDX: 25.14 (+0.13)
PharmaCyte Biotech's Cancer and Diabetes Treatments Airing Nationwide on Discovery Channel
GlobeNewswire - Mon Jun 29, 7:30AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its technology and treatments will be featured on the Discovery Channel and ION Network tomorrow morning, June 30, 2015, from 7:00-7:30 a.m. EDT and PDT, except on DISH Network which airs using the EDT time zone. PharmaCyte Biotech's story will air on Discovery Channel and ION Network's news magazine series "NewsWatch," a source for breaking consumer, technology, travel, health and entertainment news since 1990.
PharmaCyte Biotech's Dr. Mark Rabe Discusses the Significance of Schedule 1 License to Company's Future in Cannabis Research
Marketwired - Thu Jun 18, 8:02AM CDT
PharmaCyte Biotech (OTCQB: PMCB) announced this week that the Company is able to advance its Cannabis research now that its research partner, The University of Northern Colorado (UNC), successfully obtained a Schedule 1 license from the U.S. Drug Enforcement Agency or the DEA. This license will allow PharmaCyte Biotech to continue development of tumor-targeted treatments for serious and deadly cancers by utilizing cannabinoid prodrugs in combination with PharmaCyte Biotech's signature live-cell encapsulation technology, Cell-in-a-Box®.
PharmaCyte Biotech Showcasing Technology and Treatments at 2015 BIO International Convention
GlobeNewswire - Tue Jun 16, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, JD, and its Chief Operating Officer, Gerald W. Crabtree, Ph.D., have scheduled meetings to showcase PharmaCyte Biotech's technology and treatments for cancer and diabetes to the media, large biotechnology firms and institutional investors at the 2015 BIO International Convention being held June 15-18, 2015, at the Philadelphia Convention Center in Philadelphia, Pennsylvania.
PharmaCyte Biotech Advances Cannabinoid Research With Schedule 1 License
GlobeNewswire - Mon Jun 15, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its research partner, the University of Northern Colorado (UNC), successfully obtained a Schedule 1 license from the U.S. Drug Enforcement Agency (DEA) enabling the company to continue development of tumor-targeted treatments for serious and deadly cancers by utilizing cannabinoid prodrugs in combination with Cell-in-a-Boxlive cell encapsulation.
PharmaCyte Biotech's Diabetes Treatment to Be Presented at Austrodrugs 2015
GlobeNewswire - Fri Jun 12, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that the company's diabetes treatment and the research program of its international Diabetes Consortium will be presented at the Austrodrugs 2015 conference to be held on June 12 in Vienna, Austria. The Austrodrugs conference is one of the leading disease treatment development meetings in central Europe.
PharmaCyte Biotech Officers to Attend 2015 BIO International Convention
GlobeNewswire - Wed Jun 10, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, JD, and its Chief Operating Officer, Gerald W. Crabtree, Ph.D., will attend the 2015 BIO International Convention to be held June 16-18, 2015, at the Philadelphia Convention Center in Philadelphia, Pennsylvania.
PharmaCyte Biotech's Contract Research Organization Voted Australia's Favorite CRO for 2015
GlobeNewswire - Tue Jun 09, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that Clinical Network Services (CNS), the Contract Research Organization (CRO) chosen by PharmaCyte Biotech to prepare for and conduct its upcoming Phase 2b clinical trial in pancreatic cancer, has been voted Australia's favorite CRO for 2015.
PharmaCyte Biotech's Cancer Treatment Shows "Complete Tumor Remission" in Published Preclinical Study
Marketwired - Wed Jun 03, 8:30AM CDT
PharmaCyte Biotech's (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate video by the company. In that video, PharmaCyte revealed that its cancer treatment of Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide was able to produce "complete tumor remission in all animals" that received the treatment on days 2-6 of a previously published preclinical study.
PharmaCyte Biotech Releases Corporate Video
GlobeNewswire - Mon Jun 01, 6:48AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it has launched a new corporate video. In the video viewers will learn the PharmaCyte Biotech story first hand through interviews and footage shot in Singapore, Thailand, Sweden and Arizona.
PharmaCyte Biotech to Conduct Additional Study on Malignant Ascites
GlobeNewswire - Fri May 29, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it is contracting with Translational Drug Development (TD2) in Scottsdale, Arizona, to conduct an additional preclinical study related to determining the effectiveness of its Cell-in-a-Box live-cell encapsulation technology together with the anticancer drug ifosfamide in slowing the accumulation of fluid in the abdomen that accompanies the growth of pancreatic and other abdominal cancerous tumors. This fluid is commonly known as "malignant ascites fluid."
PharmaCyte Biotech to Attend Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Tue May 26, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree will attend the American Society of Clinical Oncology's (ASCO) 51 annual meeting to be held May 29 through June 2, 2015, at McCormick Place in Chicago. The theme of this year's meeting is "Illumination & Innovation."
Cannabis-Infused Consumer Products Fuel a Series of New Launches, Spin-Offs, Acquisitions & Growth Opportunities As Legalized Operations Continue to Expand Nationally
PR Newswire - Tue Jul 14, 7:45AM CDT
As more and more states move to legalizing cannabis & marijuana and while other states are now allowing medicinal use of the drug, venture capital & money has poured into companies that seem poised to profit from cannabis-based products, drugs & applications used for treating various illnesses and diseases. Cannabis Operations Companies worth noting are North American Cannabis Holdings, Inc. (OTC: USMJ), Totally Hemp Crazy, Inc. (OTC: THCZ), Hemp, Inc. (OTC: HEMP), Medbox, Inc. (OTC: MDBX) and PharmaCyte Biotech (OTC: PMCB).
INSY: 39.89 (+0.70)
PharmaCyte Biotech's Cell-in-a-Box Technology Makes Good Cancer Drugs Better
Marketwired - Mon Jul 13, 8:02AM CDT
While many biotech companies are working on new oncology drugs, what's often unappreciated about cancer treatments is how a key improvement in the way drugs are delivered can make a world of difference in their effectiveness. A young and enterprising biotechnology R&D firm called PharmaCyte Biotech (OTCQB: PMCB) understands this, and has not only embraced the benefit of improved dosing methods, but has developed a breakthrough that could change the way we altogether think about pharmaceuticals.
Penny Stocks Research for Thinspace, Pharmacyte Biotech, MaryJane, TOTALLY HEMP CRAZY, EKSO BIONICS, and Anavex Life Sciences
PR Newswire - Fri Jul 10, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Thinspace (OTCMKTS:THNS), Pharmacyte Biotech (OTCMKTS
MCB), MaryJane (OTCMKTS:MJMJ), TOTALLY HEMP CRAZY (OTCMKTS:THCZ), EKSO BIONICS (OTCBB:EKSO), and Anavex Life Sciences (OTCMKTS:AVXL). PharmaCyte Biotech Appoints American Stock Transfer as New Stock Transfer Agent
GlobeNewswire - Thu Jul 09, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that, effective July 10, 2015, American Stock Transfer & Trust Company ("AST" will replace Signature Stock Transfer as its stock transfer and dividend disbursing agent. Small Cap IR Initiates Analyst Coverage - PharmaCyte Biotech Drug Delivery Platform Limited only by Imagination
PR Newswire - Thu Jul 09, 8:15AM CDT
Small Cap IR issues report: PharmaCyte Biotech, Inc. (OTCQB: PMCB) "Cell-in-a-Box" platform exhibits significant potential. Any cell type could potentially be implanted in the body without need for administration of any drugs that decrease the body's immune response. This is important for potential therapies and will dramatically increase versatility and value of this technology into the future. The PMCB platform is a cellulose based "bead" containing live cells. The porous nature of the beads allowed nutrients to enter and support the health of the encapsulated cells. In addition, beads are porous enough to permit activated drugs or other biological substances to leave and provide benefit to their surrounding environment.
Penny Stocks Alerts for Liquidmetal Technologies, MaryJane Group, Thinspace Technology, Pharmacyte Biotech, COIN CITADEL, and Local Corporation
PR Newswire - Tue Jun 30, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Liquidmetal Technologies (OTCMKTS:LQMT), MaryJane Group (OTCMKTS:MJMJ), Thinspace Technology (OTCMKTS:THNS), Pharmacyte Biotech (OTCMKTS
MCB), COIN CITADEL (OTCMKTS:CCTL), and Local Corporation (NASDAQ:LOCM). LOCM: 0.09 (+0.03)
PharmaCyte Biotech Releases HealthWatch Segment Featured on Discovery Channel
GlobeNewswire - Tue Jun 30, 7:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its technology and treatments were featured on the Discovery Channel and ION Network this morning. Discovery Channel and ION Network's news magazine series, "NewsWatch," aired the company's story in a 3:42 "HealthWatch" segment that highlighted the companies efforts to bring both cancer and diabetes treatments to market. With the Mainstream Accepting The Use of Cannabis-Infused Products, Treats & Beverages, New & Innovative Operations Continue to Lead to Growth in the Cannabis Industry
PR Newswire - Tue Jun 30, 7:30AM CDT
As additional states nationwide ease restrictions and prepare for legalized marijuana & hemp availability and new cannabis-infused products and services are introduced to consumers, it's high time that the U.S. mainstream were able to consume cannabis legally at cafes, bistros, bars and restaurants. Cannabis Companies in focus are: North American Cannabis Holdings, Inc. (OTC: USMJ), Totally Hemp Crazy Inc. (OTC: THCZ), PharmaCyte Biotech (OTC: PMCB), Easton Pharmaceuticals Inc. (OTC: EAPH), Hemp, Inc. (OTC: HEMP) and The MaryJane Group, Inc. (OTC:MJMJ)
3 Small-Cap Biotech Stocks That Are Challenging the Status Quo
ACCESSWIRE - Mon Jun 29, 8:01AM CDT
WHITEFISH, MT / ACCESSWIRE / June 29, 2015 / Small-cap biotech stocks have been top performers so far this year, with the PowerShares S&P SmallCap Healthcare ETF (NASDAQ: PSCH) returning 25%, which is 5x better than the SPDR S&P 500 ETF's (NYSE: SPY) 5% return. Investors may want to consider adding exposure to this asset class given its outperformance and lower correlation with the overall U.S. equity market.
SPY: 210.61 (-0.07), PSCH: 73.60 (-0.49), AXDX: 25.14 (+0.13)
PharmaCyte Biotech's Cancer and Diabetes Treatments Airing Nationwide on Discovery Channel
GlobeNewswire - Mon Jun 29, 7:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its technology and treatments will be featured on the Discovery Channel and ION Network tomorrow morning, June 30, 2015, from 7:00-7:30 a.m. EDT and PDT, except on DISH Network which airs using the EDT time zone. PharmaCyte Biotech's story will air on Discovery Channel and ION Network's news magazine series "NewsWatch," a source for breaking consumer, technology, travel, health and entertainment news since 1990. PharmaCyte Biotech's Dr. Mark Rabe Discusses the Significance of Schedule 1 License to Company's Future in Cannabis Research
Marketwired - Thu Jun 18, 8:02AM CDT
PharmaCyte Biotech (OTCQB: PMCB) announced this week that the Company is able to advance its Cannabis research now that its research partner, The University of Northern Colorado (UNC), successfully obtained a Schedule 1 license from the U.S. Drug Enforcement Agency or the DEA. This license will allow PharmaCyte Biotech to continue development of tumor-targeted treatments for serious and deadly cancers by utilizing cannabinoid prodrugs in combination with PharmaCyte Biotech's signature live-cell encapsulation technology, Cell-in-a-Box®.
PharmaCyte Biotech Showcasing Technology and Treatments at 2015 BIO International Convention
GlobeNewswire - Tue Jun 16, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, JD, and its Chief Operating Officer, Gerald W. Crabtree, Ph.D., have scheduled meetings to showcase PharmaCyte Biotech's technology and treatments for cancer and diabetes to the media, large biotechnology firms and institutional investors at the 2015 BIO International Convention being held June 15-18, 2015, at the Philadelphia Convention Center in Philadelphia, Pennsylvania. PharmaCyte Biotech Advances Cannabinoid Research With Schedule 1 License
GlobeNewswire - Mon Jun 15, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its research partner, the University of Northern Colorado (UNC), successfully obtained a Schedule 1 license from the U.S. Drug Enforcement Agency (DEA) enabling the company to continue development of tumor-targeted treatments for serious and deadly cancers by utilizing cannabinoid prodrugs in combination with Cell-in-a-Boxlive cell encapsulation. PharmaCyte Biotech's Diabetes Treatment to Be Presented at Austrodrugs 2015
GlobeNewswire - Fri Jun 12, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that the company's diabetes treatment and the research program of its international Diabetes Consortium will be presented at the Austrodrugs 2015 conference to be held on June 12 in Vienna, Austria. The Austrodrugs conference is one of the leading disease treatment development meetings in central Europe. PharmaCyte Biotech Officers to Attend 2015 BIO International Convention
GlobeNewswire - Wed Jun 10, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, JD, and its Chief Operating Officer, Gerald W. Crabtree, Ph.D., will attend the 2015 BIO International Convention to be held June 16-18, 2015, at the Philadelphia Convention Center in Philadelphia, Pennsylvania. PharmaCyte Biotech's Contract Research Organization Voted Australia's Favorite CRO for 2015
GlobeNewswire - Tue Jun 09, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that Clinical Network Services (CNS), the Contract Research Organization (CRO) chosen by PharmaCyte Biotech to prepare for and conduct its upcoming Phase 2b clinical trial in pancreatic cancer, has been voted Australia's favorite CRO for 2015. PharmaCyte Biotech's Cancer Treatment Shows "Complete Tumor Remission" in Published Preclinical Study
Marketwired - Wed Jun 03, 8:30AM CDT
PharmaCyte Biotech's (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate video by the company. In that video, PharmaCyte revealed that its cancer treatment of Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide was able to produce "complete tumor remission in all animals" that received the treatment on days 2-6 of a previously published preclinical study.
PharmaCyte Biotech Releases Corporate Video
GlobeNewswire - Mon Jun 01, 6:48AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it has launched a new corporate video. In the video viewers will learn the PharmaCyte Biotech story first hand through interviews and footage shot in Singapore, Thailand, Sweden and Arizona. PharmaCyte Biotech to Conduct Additional Study on Malignant Ascites
GlobeNewswire - Fri May 29, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it is contracting with Translational Drug Development (TD2) in Scottsdale, Arizona, to conduct an additional preclinical study related to determining the effectiveness of its Cell-in-a-Box live-cell encapsulation technology together with the anticancer drug ifosfamide in slowing the accumulation of fluid in the abdomen that accompanies the growth of pancreatic and other abdominal cancerous tumors. This fluid is commonly known as "malignant ascites fluid." PharmaCyte Biotech to Attend Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Tue May 26, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree will attend the American Society of Clinical Oncology's (ASCO) 51 annual meeting to be held May 29 through June 2, 2015, at McCormick Place in Chicago. The theme of this year's meeting is "Illumination & Innovation." 
